サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1712541

胃がん治療の世界市場：2025年～2033年

Global Gastric Cancer Treatment Market - 2025-2033

出版日
ページ情報
英文 180 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
胃がん治療の世界市場：2025年～2033年
出版日: 2025年04月22日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の胃がん治療の市場規模は2024年に58億2,000万米ドルとなりました。同市場は、2033年には146億6,000万米ドルに達すると予測され、予測期間の2025年～2033年のCAGRは10.9%となる見込みです。

胃がんは、胃を覆う細胞から始まるがんの一種です。胃がんは世界で最も一般的かつ致死的ながんのひとつであり、特に東アジア、欧州、南米の一部で流行しています。胃がんは胃のどの部分にも発生し、食道、膵臓、肝臓、リンパ節など他の臓器に転移することもあります。

胃がんは主に胃を覆う上皮細胞から発生し、胃がんの最も一般的なタイプである腺がんに至ります（症例の約90～95％）。しかし、胃がんには、リンパ腫（リンパ組織のがん）、消化管間質腫瘍（GIST）、神経内分泌腫瘍など、他のまれな病型も含まれます。

胃がん治療における最も注目すべき進歩の1つは、HER2標的治療薬の開発です。HER2（ヒト上皮成長因子受容体2）は一部の胃がん細胞で過剰発現するタンパク質で、制御不能な細胞増殖を引き起こします。HER2を標的とするモノクローナル抗体であるトラスツズマブ（ハーセプチン）は、HER2陽性胃がんに対する画期的な治療法でした。この治療の成功により、進行胃がんに対する化学療法との併用療法が広く行われるようになっています。

例えば、2024年10月、Astellas Pharma Inc.は、米国食品医薬品局（FDA）より、HER2陽性胃がんに対する化学療法との併用療法が承認されたと発表しました。VYLOY（zolbetuximab-clzb）は、切除不能または転移性の局所進行性ヒト上皮成長因子受容体2（HER2）陰性の胃または胃食道接合部（GEJ）腺がんで、FDAが承認した検査で腫瘍がクローディン（CLDN）18.2陽性である成人の一次治療薬として、フルオロピリミジンおよびプラチナ製剤を含む化学療法との併用が承認されたとFDA（米国食品医薬品局）が2024年10月に発表しました。VYLOYは米国で承認された最初で唯一のCLDN18.2標的治療薬です。

標的治療の進歩の高まりは、胃がん治療市場の成長の大きな原動力となっています。より個別化された効果的な治療法へのシフト、FDAによる新薬の承認、市場受容の拡大、患者の生存率の向上などが、この成長に寄与しています。この分野の研究が進むにつれて、標的治療薬がさらに洗練され、胃がん患者に大きな希望をもたらし、市場がさらに拡大することが期待されます。

胃がん治療が大きく進歩したにもかかわらず、副作用や安全性への懸念は依然として胃がん治療における大きな課題となっています。従来の治療と標的治療の両方に関連する副作用は、しばしば患者の処方されたレジメンの順守を妨げ、QOLに影響を与え、治療レジメンを複雑にします。こうした懸念が、胃がん治療市場の普及と成長を妨げています。

化学療法は依然として胃がん治療の要ですが、さまざまな重篤な副作用を伴います。これらは投与量の減少、治療の中止、QOLの低下につながり、最終的に市場成長の妨げとなります。標的治療や免疫療法は胃がん治療に革命をもたらしましたが、これらの治療にもリスクがないわけではありません。化学療法に比べれば副作用は少ない傾向にありますが、それでも重篤な免疫関連有害事象（irAE）やオフターゲット効果を引き起こす可能性があります。

胃がんの発生率は上昇しています。DataM intelligenceの推計によると、2024年には世界で102万人近い有病率が予測されています。最も有病率が高い地域はアジア太平洋で、1億9,028万例です。スクリーニングによる早期発見、治療方法の改善、公衆衛生対策の改善が、先進国における罹患率と死亡率の低下に寄与しています。しかし、胃がんは、特に発展途上国やリスクの高い人々の間で、引き続き大きなヘルスケア上の負担となっています。

当レポートでは、世界の胃がん治療市場について調査し、市場の概要とともに、がんタイプ別、治療タイプ別、投与経路別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 経営者の洞察と重要なポイント

第3章 市場力学

  • 影響要因
    • 促進要因
    • 抑制要因
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーとパイオニア
  • 最新の開発とブレークスルー
  • 規制と償還の情勢
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • パイプライン分析
  • 疫学分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向
  • キーオピニオンリーダー

第5章 胃がん治療市場（がんタイプ別）

  • 非噴門（遠位）胃がん
  • 近位胃がん
  • びまん性胃がん
  • リンパ腫
  • 消化管間質腫瘍
  • カルチノイド腫瘍
  • 腺がん
  • その他

第6章 胃がん治療市場（治療タイプ別）

  • 化学療法
  • 放射線治療
  • 標的療法
  • 免疫療法
  • 手術
  • その他

第7章 胃がん治療市場（投与経路別）

  • 注射
  • 経口

第8章 胃がん治療市場、地域別市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • 中東・アフリカ

第9章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要市場参入企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併・買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第10章 企業プロファイル

  • Merck &Co., Inc.
    • 会社概要
    • 製品ポートフォリオ
    • 財務概要
    • 主な発展
    • SWOT分析
  • Eli Lilly and Company
  • Genentech USA, Inc.
  • Pfizer Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • Blueprint Medicines Corporation
  • Daiichi Sankyo, Inc.
  • BeiGene, Ltd.
  • Ipsen Biopharmaceuticals Inc.
  • Taiho Oncology, Inc.
  • Deciphera Pharmaceuticals, LLC.

第11章 仮定と調査手法

第12章 付録

目次
Product Code: PH9517

The global gastric cancer treatment market size reached US$ 5.82 billion in 2024 and is expected to reach US$ 14.66 billion by 2033, growing at a CAGR of 10.9% during the forecast period 2025-2033.

Gastric cancer, also known as stomach cancer, refers to a type of cancer that begins in the cells lining the stomach. It is one of the most common and deadly forms of cancer worldwide, particularly prevalent in East Asia, Europe, and parts of South America. Gastric cancer can develop in any part of the stomach and may spread to other organs, such as the esophagus, pancreas, liver, and lymph nodes.

Gastric cancer primarily originates from the epithelial cells that line the stomach, leading to adenocarcinoma, which is the most common type of gastric cancer (around 90-95% of cases). However, gastric cancer can also include other, rarer forms such as lymphoma (cancer of lymphatic tissue), gastrointestinal stromal tumors (GISTs), and neuroendocrine tumors.

Market Dynamics: Drivers & Restraints

Rising advancements in targeted therapies are significantly driving the gastric cancer treatment market growth

One of the most notable advancements in gastric cancer treatment has been the development of HER2-targeted therapies. HER2 (human epidermal growth factor receptor 2) is a protein overexpressed in some gastric cancer cells, leading to uncontrolled cell growth. Trastuzumab (Herceptin), a monoclonal antibody targeting HER2, has been a groundbreaking treatment for HER2-positive gastric cancer. The success of this treatment has led to its widespread use in combination with chemotherapy for advanced gastric cancer.

For instance, in October 2024, Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) approved VYLOY (zolbetuximab-clzb) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test. VYLOY is the first and only CLDN18.2-targeted therapy approved in the U.S.

The rising advancements in targeted therapies have been a significant driver for the growth of the gastric cancer treatment market. The shift towards more personalized and effective treatments, combined with the FDA approvals of new drugs, the growing market acceptance, and the increased survival rates in patients, all contribute to this growth. As the research in this field continues to progress, it is expected that targeted therapies will become even more refined, offering greater hope for gastric cancer patients and expanding the market further.

Side effects and safety concerns associated with the treatment are hampering the market growth

Despite the significant advancements in gastric cancer treatment, side effects and safety concerns continue to pose major challenges in the management of the disease. The adverse effects associated with both traditional and targeted therapies often deter patients from adhering to prescribed regimens, impact their quality of life, and complicate treatment regimens. These concerns, in turn, hinder the widespread adoption and growth of the gastric cancer treatment market.

Chemotherapy remains a cornerstone of treatment for gastric cancer, but it is associated with a range of severe side effects. These can lead to dose reductions, discontinuation of therapy, and decreased quality of life, which ultimately hampers market growth. While targeted therapies and immunotherapies have revolutionized gastric cancer treatment, these therapies are not without their risks. Although they tend to have fewer side effects than chemotherapy, they can still cause severe immune-related adverse events (irAEs) or off-target effects.

Epidemiology Analysis

The incidence of gastric cancer is rising. As per DataM intelligence estimates, nearly 1.02 million prevalent cases are estimated worldwide in 2024. The region with the highest prevalence is the Asia-Pacific, accounting for 190.28 million cases. Early detection through screening, better treatment options, and improved public health measures have contributed to the decline in incidence and mortality rates in developed countries. However, gastric cancer continues to present a major healthcare burden, particularly in developing nations and among high-risk populations.

Segment Analysis

The global gastric cancer treatment market is segmented based on cancer type, treatment type, route of administration, and region.

Treatment Type:

The chemotherapy segment is expected to dominate the gastric cancer treatment market with the highest market share

Chemotherapy is frequently used as the primary treatment in advanced gastric cancer, often in combination with targeted therapies or immunotherapy. In cases where surgery is not possible, chemotherapy serves as a crucial palliative treatment to control symptoms, slow the disease's progression, and improve survival rates. For instance, FOLFOX (a combination of 5-fluorouracil (5-FU), oxaliplatin, and leucovorin) is a standard chemotherapy regimen used in gastric cancer. This regimen is particularly effective for advanced gastric cancer and has been widely adopted.

Chemotherapy is frequently combined with targeted therapies like trastuzumab, ramucirumab, and nivolumab to enhance efficacy, especially in advanced or metastatic gastric cancer. These combination regimens have become the standard of care in many treatment protocols. The growing trend of combining chemotherapy with newer therapies has expanded its market dominance, as it remains the central component of first-line and second-line treatment regimens in both HER2-positive and HER2-negative gastric cancers.

Geographical Analysis

North America is expected to hold a significant position in the global gastric cancer treatment market with the highest market share

The FDA (U.S. Food and Drug Administration) and Health Canada are at the forefront of regulatory approvals for new cancer therapies, including those for gastric cancer. These agencies have fast-tracked and drug approvals for novel treatments like TEVIMBRA (tislelizumab-jsgr), nivolumab (Opdivo), trastuzumab (Herceptin), and ramucirumab (Cyramza). This further accelerates the market growth in the region with various effective treatments.

For instance, in December 2024, BeiGene, Ltd., a global oncology company that intends to change its name to BeOne Medicines Ltd., announced the U.S. Food and Drug Administration (FDA) approved TEVIMBRA (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1 (>=1).

North America has been a leader in adopting targeted therapies and immunotherapies, which are increasingly used to treat gastric cancer. The region's healthcare system supports the use of expensive, but highly effective, biologics and immunotherapy drugs that target specific proteins or immune checkpoints involved in cancer progression. For instance, Trastuzumab (Herceptin) is widely used for HER2-positive gastric cancer, and its combination with chemotherapy has led to better survival rates. Nivolumab (Opdivo), an immune checkpoint inhibitor, is also approved for use in gastric cancer and has been shown to significantly improve survival in combination with chemotherapy.

Competitive Landscape

Top companies in the gastric cancer treatment market include Merck & Co., Inc., Eli Lilly and Company, Genentech USA, Inc., Pfizer Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Blueprint Medicines Corporation, Daiichi Sankyo, Inc., BeiGene, Ltd., Ipsen Biopharmaceuticals Inc., Taiho Oncology, Inc., and Deciphera Pharmaceuticals, LLC., and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global gastric cancer treatment market report delivers a detailed analysis with 68 key tables, more than 61 visually impactful figures and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Cancer Type
  • 2.4. Snippet by Treatment Type
  • 2.5. Snippet by Route of Administration
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Advancements in Targeted Therapies
      • 3.1.1.2. Expanding Clinical Trials and Research Investment
    • 3.1.2. Restraints
      • 3.1.2.1. Side Effects and Safety Concerns
      • 3.1.2.2. High Treatment Costs
    • 3.1.3. Opportunity
      • 3.1.3.1. Advancements in Treatment Options
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established Leaders with Largest Marketing Brand
    • 4.1.3. Market Leaders with Established Products
  • 4.2. Latest Developments and Breakthroughs
  • 4.3. Regulatory and Reimbursement Landscape
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. Asia Pacific
    • 4.3.4. Latin America
    • 4.3.5. Middle East & Africa
  • 4.4. Porter's Five Forces Analysis
  • 4.5. Supply Chain Analysis
  • 4.6. Patent Analysis
  • 4.7. SWOT Analysis
  • 4.8. Pipeline Analysis
  • 4.9. Epidemiology Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Gastric Cancer Treatment Market, By Cancer Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 5.1.2. Market Attractiveness Index, By Cancer Type
  • 5.2. Non-Cardia (Distal) Stomach Cancer*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Proximal Stomach Cancer
  • 5.4. Diffuse Stomach Cancer
  • 5.5. Lymphomas
  • 5.6. Gastrointestinal Stromal Tumors
  • 5.7. Carcinoid Tumors
  • 5.8. Adenocarcinoma
  • 5.9. Others

6. Gastric Cancer Treatment Market, By Treatment Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 6.1.2. Market Attractiveness Index, By Treatment Type
  • 6.2. Chemotherapy*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Capecitabine
    • 6.2.4. Cisplatin
    • 6.2.5. Docetaxel
    • 6.2.6. Doxorubicin
    • 6.2.7. Epirubicin
    • 6.2.8. Fluorouracil (5-FU)
    • 6.2.9. Irinotecan
    • 6.2.10. Leucovorin
    • 6.2.11. Oxaliplatin
    • 6.2.12. Paclitaxel
    • 6.2.13. Others
  • 6.3. Radiation Therapy
  • 6.4. Targeted Therapy
    • 6.4.1. Ramucirumab
    • 6.4.2. Regorafenib
    • 6.4.3. Trastuzumab
    • 6.4.4. Zolbetuximab
    • 6.4.5. Others
  • 6.5. Immunotherapy
    • 6.5.1. Nivolumab
    • 6.5.2. Pembrolizumab
  • 6.6. Surgery
    • 6.6.1. Gastrectomy
    • 6.6.2. Gastrojejunostomy
    • 6.6.3. Others
  • 6.7. Others

7. Gastric Cancer Treatment Market, By Route of Administration

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.1.2. Market Attractiveness Index, By Route of Administration
  • 7.2. Injectable*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Oral

8. Gastric Cancer Treatment Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. UK
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. Asia-Pacific
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. China
      • 8.4.6.2. India
      • 8.4.6.3. Japan
      • 8.4.6.4. South Korea
      • 8.4.6.5. Rest of Asia-Pacific
  • 8.5. South America
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. Brazil
      • 8.5.6.2. Argentina
      • 8.5.6.3. Rest of South America
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Merck & Co., Inc.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue's
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Eli Lilly and Company
  • 10.3. Genentech USA, Inc.
  • 10.4. Pfizer Inc.
  • 10.5. Astellas Pharma Inc.
  • 10.6. Bristol-Myers Squibb Company
  • 10.7. Blueprint Medicines Corporation
  • 10.8. Daiichi Sankyo, Inc.
  • 10.9. BeiGene, Ltd.
  • 10.10. Ipsen Biopharmaceuticals Inc.
  • 10.11. Taiho Oncology, Inc.
  • 10.12. Deciphera Pharmaceuticals, LLC.

LIST NOT EXHAUSTIVE

11. Assumptions and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us